



V GO NORTE INTERNATIONAL GU DEBATES

8th - 9th

OCTOBER
2026



X #GonorteGUDebates

VENUE

PARADOR DE LIMPIAS
THURSDAY, OCTOBER 8th
Fuente del Amor s/n,
39820, Limpias (Cantabria)

08:30

PRELIMINAR SCIENTIFIC PROGRAMME

REGISTRATION

ORGANIZED BY



GONORTE
Grupo Oncológico



PRELIMINAR SCIENTIFIC PROGRAMME

THURSDAY, OCTOBER 8TH, 2026

- 09:00-09:10 OPENING**
 Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander
 Dra. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona
- 09:10-11:50 SESSION 1. NON-MUSCLE INVASIVE BLADDER CANCER:
 ARE NEW TREATMENTS READY FOR PRIME TIME?**
Chairs:
 Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
 Dr. José Rubio, Urology Department, Hospital Vithas Valencia 9 de Octubre
- 09:15-09:30 **Clinical Vignette**
- 09:30-09:45 **NMIBC: What do I need to know to understand drug development in this setting?**
 Dr. Jozefina Casuscelli, Clinic and Polyclinic for Urology, LMU University Hospital, Munich, Germany
- 09:45-10:00 **New I.O. based treatments are ready for prime time in BCG naïve NMIBC patients**
 Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid
- 10:00-10:15 **New IO. based treatments are not ready for prime time in BCG naïve NMIBC patients**
 Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid
- 10:15-10:30 **Radiotherapy-based treatments as an emerging strategy in HR NMIBC**
 TBD
- 10:30-10:45 **Intravesical drug-delivery systems in BCG-naïve disease: evidence and limitations**
 Dr. Bernardo Herrera. Hospital Universitario Virgen de la Victoria, Malaga
- 10:45-11:15 **Discussion**
- 11:15-11:50 Coffee Break ☕**



- 11:50-13:35** **SESSION 2. MUSCLE INVASIVE BLADDER CANCER: APPROACHING A CLASSIC DISEASE IN A NEW ERA**
Chairs:
 Dra. Elena Sevillano, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid
 Dr. Jerónimo Barrera, Urological Radiology Department, Hospital Clínico San Carlos, Madrid
- 11:50-12:05 **Clinical Vignette**
- 12:05-12:20 **Do I have to convince my radiologist to perform MRI in MIBC? From its role in initial staging to potential biomarker of response**
 TBD
- 12:20-12:35 **Variant histologies in MIBC: Which ones, how often and how much should condition my perioperative treatment selection?**
 Dra. Ainara Azueta, Pathology Department, Hospital Universitario Basurto, Bilbao
- 12:35-12:50 **Should the genomic profiling or the molecular subtypes in UC condition my treatment choice in MIBC?**
 TBD
- 13:50-13:05 **Do blood or urine biomarkers have any role in guiding perioperative treatment?**
 Dr. Yohan Lorient, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
- 13:05-13:35 **Discussion**
- 13:35-14:20** **MEET THE EXPERT SYMPOSIUM**
- 14:20-15:45** **Lunch Break** 🍴
- 15:45-17:15** **SESSION 3. DEBATING BEST TREATMENT APPROACH IN MUSCLE INVASIVE BLADDER CANCER**
Chairs:
 Dr. Enrique Grande, Medical Oncology Department, Quirónsalud, Madrid
 Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid
- 15:45-16:05 **Are perioperative ADC combinations the new default strategy?**
 TBD



- 16:05-16:25 **Perioperative chemotherapy plus checkpoint inhibition:
Which and to whom in 2026?**
Dr. Syed A. Hussain, Medical Oncology Department, University of Sheffield
and Sheffield Teaching Hospitals NHS Trust, UK
- 16:25-16:45 **What if I want to preserve my bladder? Current and future bladder
sparing strategies in MBIC**
Dr. Terence Friedlander, Genitourinary Medical Oncology, University of
California San Francisco, USA
- 16:45-17:15 **Discussion**
- 17:15-18:00 **MEET THE EXPERT SYMPOSIUM**
- 18:00-18:35 **Coffee Break ☕**
- 18:35-19:15 **MEET THE EXPERT SYMPOSIUM**
- 19:15 -19:45 **KEYNOTE LECTURE**
Treating Bladder Cancer in 2030: What does the future hold?
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers
Program, University of Washington, Clinical Research Division, Fred
Hutchinson Cancer Center
- 19:45-19:50 **CLOSING OF THE DAY**
- 20:00 **GET TOGETHER COKTAIL AND DINNER**



FRIDAY, OCTOBER 9th

08:00- 08:15

OPENING

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza

08:15-09:35

SESSION 4. PROSTATE CANCER

Chairs:

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Dra. Estefania Linares, Urology Department, Hospital Universitario La Paz, Madrid

08:15-08:30

The perioperative treatment of high-risk Prostate Cancer in 2026: Where do things stand after PROTEUS?

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncología – IVO, Valencia

08:30-08:45

Advanced hormone sensitive disease: Is the triplet vs doublet debate over?

Juan Francisco Rodríguez-Moreno, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

08:45-09:00

Optimizing androgen receptor-targeted therapy in mCRPC in 2026: Present options and near future

Dr. Charles J. Ryan, Genitourinary Medical Oncologist Department, Memorial Sloan Kettering Cancer Center, New York, USA

09:00-09:15

Positioning PARP Inhibitors in mCRPC: The 2026 Landscape

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09:15 - 09:35

Discussion

09:35-10:20

MEET THE EXPERT SYMPOSIUM

10:20-10:55

Coffee Break ☕

11:00-11:47

MEET THE EXPERT SYMPOSIUM



11:50-13:05

SESSION 5. HIGH RISK LOCALIZED RENAL CANCER

Chairs:

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Mario Dominguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

11:50-12:00

Clinical Vignette

12:00-12:15

Estimating risk after nephrectomy: Are we all in the same page? Are we overtreating?

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

12:15-12:30

Reshaping adjuvant treatment in 2026: Is angiogenesis back?

Dr. Dan Heng, Medical Oncology Department, Calgary, Canada

12:30-12:45

I am in favor of systemic treatment first? Role of neoadjuvant treatment in high risk RCC

Dr. Axel Bex, Netherlands Cancer Institute, Amsterdam

12:45-13:05

Discussion

13.05-14:10

SESSION 6. ADVANCED RENAL CANCER AND OTHER VLH MEDIATED DISEASES

Chairs:

Dr. Jesús García Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

TBD

13:05-13:20

First line mRCC: IO-IO vs IO-TKI: Is the eternal debate over?

Dr Lisa Pickering, Medical Oncology Department, The Royal Marsden NHS Foundation Trust, London, UK

13:20-13:35

Sequencing treatments in the advanced setting: Is it clear in 2026?

Dr. Cristina Suárez, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Barcelona

13:35-13:50

Inhibiting HIF in VHL syndrome: A life changer for patients?

Dr. Guillermo De Velasco, Medical Oncology Department, Hospital 12 de Octubre, Madrid

13:50-14:10

Discussion



14:10-14:40

CLOSING LECTURE:

Curing the Incurable? Rethinking long-term disease control in advanced RCC

Dr. Dan Heng, Medical Oncology Department, Calgary, Canada

14:40

CLOSING OF THE SYMPOSIUM

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao



V GO NORTE INTERNATIONAL GU DEBATES

8th-9th OCTOBER
2026



SPONSORS

PLATINUM



SILVER



BRONZE



Secretaría técnica



Barcelona · Madrid

93 451 17 24

info@tacticsmd.net

www.tacticsmd.net